Tumor invasion in draining lymph nodes is associated with Treg accumulation in breast cancer patients.
Journal
Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555
Informations de publication
Date de publication:
29 06 2020
29 06 2020
Historique:
received:
24
01
2020
accepted:
04
06
2020
entrez:
1
7
2020
pubmed:
1
7
2020
medline:
29
8
2020
Statut:
epublish
Résumé
Tumor-draining lymph node (TDLN) invasion by metastatic cells in breast cancer correlates with poor prognosis and is associated with local immunosuppression, which can be partly mediated by regulatory T cells (Tregs). Here, we study Tregs from matched tumor-invaded and non-invaded TDLNs, and breast tumors. We observe that Treg frequencies increase with nodal invasion, and that Tregs express higher levels of co-inhibitory/stimulatory receptors than effector cells. Also, while Tregs show conserved suppressive function in TDLN and tumor, conventional T cells (Tconvs) in TDLNs proliferate and produce Th1-inflammatory cytokines, but are dysfunctional in the tumor. We describe a common transcriptomic signature shared by Tregs from tumors and nodes, including CD80, which is significantly associated with poor patient survival. TCR RNA-sequencing analysis indicates trafficking between TDLNs and tumors and ongoing Tconv/Treg conversion. Overall, TDLN Tregs are functional and express a distinct pattern of druggable co-receptors, highlighting their potential as targets for cancer immunotherapy.
Identifiants
pubmed: 32601304
doi: 10.1038/s41467-020-17046-2
pii: 10.1038/s41467-020-17046-2
pmc: PMC7324591
doi:
Substances chimiques
B7-1 Antigen
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
3272Références
Cochran, A. J. et al. Tumour–induced immune modulation of sentinel lymph nodes. Nat. Rev. Immunol. 6, 659–670 (2006).
pubmed: 16932751
Munn, D. H. & Mellor, A. L. The tumor-draining lymph node as an immune-privileged site. Immunol. Rev. 213, 146–158 (2006).
pubmed: 16972902
Tang, Q. et al. Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction. Immunity 28, 687–697 (2008).
pubmed: 18468463
pmcid: 2394854
Galimberti, V. & Cole, B. F. Axillary versus sentinel-lymph-node dissection for micrometastatic breast cancer – authors’ reply. Lancet Oncol. 14, e251–e252 (2013).
pubmed: 23725705
Giuliano, A. E. et al. Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: the ACOSOG Z0011 (Alliance) randomized clinical trial. JAMA 318, 918 (2017).
pubmed: 28898379
pmcid: 5672806
Swartz, M. A. & Lund, A. W. Lymphatic and interstitial flow in the tumour microenvironment: linking mechanobiology with immunity. Nat. Rev. Cancer 12, 210–219 (2012).
pubmed: 22362216
Jones, D., Pereira, E. R. & Padera, T. P. Growth and immune evasion of lymph node metastasis. Front. Oncol. 8, 36 (2018).
pubmed: 29527513
pmcid: 5829610
Faghih, Z. et al. Immune profiles of CD4+ lymphocyte subsets in breast cancer tumor draining lymph nodes. Immunol. Lett. 158, 57–65 (2014).
pubmed: 24326038
Peters, J. H. et al. Human secondary lymphoid organs typically contain polyclonally-activated proliferating regulatory T cells. Blood 122, 2213–2223 (2013).
pubmed: 23950176
Poindexter, N. J., Sahin, A., Hunt, K. K. & Grimm, E. A. Analysis of dendritic cells in tumor-free and tumor-containing sentinel lymph nodes from patients with breast cancer. Breast Cancer Res. 6, R408 (2004).
pubmed: 15217509
pmcid: 468660
Zuckerman, N. S. et al. Altered local and systemic immune profiles underlie lymph node metastasis in breast cancer patients. Int. J. Cancer 132, 2537–2547 (2013).
pubmed: 23136075
Plitas, G. et al. Regulatory T cells exhibit distinct features in human breast cancer. Immunity 45, 1122–1134 (2016).
pubmed: 27851913
pmcid: 5134901
Chaudhary, B. & Elkord, E. Regulatory T cells in the tumor microenvironment and cancer progression: role and therapeutic targeting. Vaccines (Basel) 4, pii: E28 (2016).
Bates, G. J. et al. Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at rsk of late relapse. JCO 24, 5373–5380 (2006).
Merlo, A. et al. FOXP3 expression and overall survival in breast cancer. JCO 27, 1746–1752 (2009).
Duhen, T., Duhen, R., Lanzavecchia, A., Sallusto, F. & Campbell, D. J. Functionally distinct subsets of human FOXP3+ Treg cells that phenotypically mirror effector Th cells. Blood 119, 4430–4440 (2012).
pubmed: 22438251
pmcid: 3362361
Kunicki, M. A., Amaya Hernandez, L. C., Davis, K. L., Bacchetta, R. & Roncarolo, M.-G. Identity and diversity of human peripheral Th and T regulatory cells defined by single-cell mass. Cytom. J. I. 200, 336–346 (2018).
van Pul, K. M. et al. Selectively hampered activation of lymph node-resident dendritic cells precedes profound T cell suppression and metastatic spread in the breast cancer sentinel lymph node. J. Immunother. Cancer 7, 133 (2019).
pubmed: 31118093
pmcid: 6530094
Kohrt, H. E. et al. Profile of immune cells in axillary lymph nodes predicts disease-free survival in breast cancer. PLoS Med. 2, e284 (2005).
pubmed: 16124834
pmcid: 1198041
Nakamura, R. et al. Accumulation of regulatory T cells in sentinel lymph nodes is a prognostic predictor in patients with node-negative breast cancer. Eur. J. Cancer 45, 2123–2131 (2009).
pubmed: 19398324
Dougan, M., Dranoff, G. & Dougan, S. K. Cancer immunotherapy: beyond checkpoint blockade. Annu. Rev. Cancer Biol. 3, 55–75 (2019).
Yost, K. E. et al. Clonal replacement of tumor-specific T cells following PD-1 blockade. Nat. Med 25, 1251–1259 (2019).
pubmed: 31359002
pmcid: 6689255
Adams, S. et al. Current landscape of immunotherapy in breast cancer: a review. JAMA Oncol. 5, 1205 (2019).
Vonderheide, R. H. et al. Tremelimumab in combination with exemestane in patients with advanced breast cancer and treatment-associated modulation of inducible costimulator expression on patient T cells. Clin. Cancer Res. 16, 3485–3494 (2010).
pubmed: 20479064
Wang, L. et al. Connecting blood and intratumoral Treg cell activity in predicting future relapse in breast cancer. Nat. Immunol. 20, 1220–1230 (2019).
pubmed: 31285626
Chen, D. S. & Mellman, I. Oncology meets immunology: the cancer-immunity cycle. Immunity 39, 1–10 (2013).
pubmed: 23890059
Ruffell, B. et al. Leukocyte composition of human breast cancer. Proc. Natl Acad. Sci. 109, 2796–2801 (2012).
pubmed: 21825174
Miyara, M. et al. Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor. Immunity 30, 899–911 (2009).
Nishikawa, H. & Sakaguchi, S. Regulatory T cells in cancer immunotherapy. Curr. Opin. Immunol. 27, 1–7 (2014).
pubmed: 24413387
Joncker, N. T. et al. Antigen-independent accumulation of activated effector/memory T lymphocytes into human and murine tumors. Int. J. Cancer 118, 1205–1214 (2006).
pubmed: 16152614
Dominguez-Villar, M., Baecher-Allan, C. M. & Hafler, D. A. Identification of T helper type 1–like, Foxp3+ regulatory T cells in human autoimmune disease. Nat. Med. 17, 673–675 (2011).
pubmed: 21540856
pmcid: 3675886
Overacre-Delgoffe, A. E. et al. Interferon-γ drives T reg fragility to promote anti-tumor immunity. Cell 169, 1130–1141.e11 (2017).
pubmed: 28552348
pmcid: 5509332
Feuerer, M., Hill, J. A., Mathis, D. & Benoist, C. Foxp3+ regulatory T cells: differentiation, specification, subphenotypes. Nat. Immunol. 10, 689–695 (2009).
pubmed: 19536194
Mahnke, Y. D., Brodie, T. M., Sallusto, F., Roederer, M. & Lugli, E. The who’s who of T-cell differentiation: human memory T-cell subsets: HIGHLIGHTS. Eur. J. Immunol. 43, 2797–2809 (2013).
pubmed: 24258910
Wang, T. et al. The different T-cell receptor repertoires in breast cancer tumors, draining lymph nodes, and adjacent tissues. Cancer Immunol. Res. 5, 148–156 (2017).
pubmed: 28039161
Lee, H.-M., Bautista, J. L. & Hsieh, C.-S. Thymic and peripheral differentiation of regulatory T cells. Adv. Immunol. 112, 25–71 (Elsevier, 2011).
Lee, W. & Lee, G. R. Transcriptional regulation and development of regulatory T cells. Exp. Mol. Med. 50, e456 (2018).
pubmed: 29520112
pmcid: 5898904
Alonso, R. et al. Induction of anergic or regulatory tumor-specific CD4+ T cells in the tumor-draining lymph node. Nat. Commun. 9, 2113 (2018).
pubmed: 29844317
pmcid: 5974295
Buchan, S. L. et al. Antibodies to costimulatory receptor 4-1bb enhance anti-tumor immunity via T regulatory cell depletion and promotion of CD8 T cell effector function. Immunity 49, 958–970.e7 (2018).
pubmed: 30446386
Zhang, T. et al. Aberrant frequency of TNFR2
Halvorsen, E. C. et al. IL-33 increases ST2
pubmed: 30713780
Pastille, E. et al. The IL-33/ST2 pathway shapes the regulatory T cell phenotype to promote intestinal cancer. Mucosal Immunol. 12, 990–1003 (2019).
pubmed: 31165767
Liu, Y. et al. FOXP3 and CEACAM6 expression and T cell infiltration in the occurrence and development of colon cancer. Oncol. Lett. 11, 3693–3701 (2016).
pubmed: 27284373
pmcid: 4888014
Gu, P. et al. Trogocytosis of CD80 and CD86 by induced regulatory T cells. Cell Mol. Immunol. 9, 136–146 (2012).
pubmed: 22307040
pmcid: 4002813
Ovcinnikovs, V. et al. CTLA-4-mediated transendocytosis of costimulatory molecules primarily targets migratory dendritic cells. Sci. Immunol. 4, eaaw0902 (2019).
Zhao, Y. et al. PD-L1:CD80 cis-heterodimer triggers the co-stimulatory receptor CD28 while repressing the inhibitory PD-1 and CTLA-4 pathways. Immunity 51, 1059–1073.e9 (2019).
pubmed: 31757674
pmcid: 6935268
Wolf, A. M. et al. Increase of regulatory T cells in the peripheral blood of cancer patients. Clin. Cancer Res. 9, 606–612 (2003).
pubmed: 12576425
Liyanage, U. K. et al. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J. Immunol. 169, 2756–2761 (2002).
pubmed: 12193750
Sun, S. et al. PD-1+ immune cell infiltration inversely correlates with survival of operable breast cancer patients. Cancer Immunol. Immunother. 63, 395–406 (2014).
pubmed: 24514954
Gupta, R. et al. The numbers of FoxP3+ lymphocytes in sentinel lymph nodes of breast cancer patients correlate with primary tumor size but not nodal status. Cancer Investig. 29, 419–425 (2011).
Zhou, X. et al. Instability of the transcription factor Foxp3 leads to the generation of pathogenic memory T cells in vivo. Nat. Immunol. 10, 1000–1007 (2009).
pubmed: 19633673
pmcid: 2729804
Overacre-Delgoffe, A. E. & Vignali, D. A. A. Treg fragility: a prerequisite for effective antitumor immunity? Cancer Immunol. Res. 6, 882–887 (2018).
pubmed: 30068755
pmcid: 6080214
Furness, A. J. S., Vargas, F. A., Peggs, K. S. & Quezada, S. A. Impact of tumour microenvironment and Fc receptors on the activity of immunomodulatory antibodies. Trends Immunol. 35, 290–298 (2014).
pubmed: 24953012
Fritz, J. M. & Lenardo, M. J. Development of immune checkpoint therapy for cancer. J. Exp. Med. 216, 1244–1254 (2019).
pubmed: 31068379
pmcid: 6547853
Buchan, S. L., Rogel, A. & Al-Shamkhani, A. The immunobiology of CD27 and OX40 and their potential as targets for cancer immunotherapy. Blood 131, 39–48 (2018).
pubmed: 29118006
Redjimi, N. et al. CXCR3+ T regulatory cells selectively accumulate in human ovarian carcinomas to limit type I immunity. Cancer Res. 72, 4351–4360 (2012).
pubmed: 22798340
Rosenberg, S. A. & Restifo, N. P. Adoptive cell transfer as personalized immunotherapy for human cancer. Science 348, 62–68 (2015).
pubmed: 25838374
pmcid: 6295668
Hu, Z., Ott, P. A. & Wu, C. J. Towards personalized, tumour-specific, therapeutic vaccines for cancer. Nat. Rev. Immunol. 18, 168–182 (2018).
pubmed: 29226910
Gu-Trantien, C. et al. CD4
pubmed: 23778140
pmcid: 3696556
Beausang, J. F. et al. T cell receptor sequencing of early-stage breast cancer tumors identifies altered clonal structure of the T cell repertoire. Proc. Natl Acad. Sci. USA 114, E10409–E10417 (2017).
pubmed: 29138313
Zemmour, D. et al. Single-cell gene expression reveals a landscape of regulatory T cell phenotypes shaped by the TCR. Nat. Immunol. 19, 291–301 (2018).
pubmed: 29434354
pmcid: 6069633
Maj, T. et al. Oxidative stress controls regulatory T cell apoptosis and suppressor activity and PD-L1-blockade resistance in tumor. Nat. Immunol. 18, 1332–1341 (2017).
pubmed: 29083399
pmcid: 5770150
Speiser, D. E., Ho, P.-C. & Verdeil, G. Regulatory circuits of T cell function in cancer. Nat. Rev. Immunol. 16, 599–611 (2016).
pubmed: 27526640
Tatari-Calderone, Z., Semnani, R. T., Nutman, T. B., Schlom, J. & Sabzevari, H. Acquisition of CD80 by human T cells at early stages of activation: functional involvement of CD80 acquisition in T cell to T cell interaction. J. Immunol. 169, 6162–6169 (2002).
pubmed: 12444120
Bhairavabhotla, R. et al. Transcriptome profiling of human FoxP3+ regulatory T cells. Hum. Immunol. 77, 201–213 (2016).
pubmed: 26686412
Schumacher, T. N. & Schreiber, R. D. Neoantigens in cancer immunotherapy. Science 348, 69–74 (2015).
pubmed: 25838375
Zacharakis, N. et al. Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer. Nat. Med. 24, 724–730 (2018).
pubmed: 29867227
pmcid: 6348479
Nowicka, M. et al. CyTOF workflow: differential discovery in high-throughput high-dimensional cytometry datasets. F1000Res 6, 748 (2017).
pubmed: 28663787
Han, A., Glanville, J., Hansmann, L. & Davis, M. M. Linking T-cell receptor sequence to functional phenotype at the single-cell level. Nat. Biotechnol. 32, 684–692 (2014).
pubmed: 24952902
pmcid: 4337815
Bolotin, D. A. et al. MiXCR: software for comprehensive adaptive immunity profiling. Nat. Methods 12, 380–381 (2015).
pubmed: 25924071